ADMA Biologics
ADMA Biologics Inc is an American commercial-stage biopharmaceutical company focused on plasma-derived biologics for infectious and immunodeficiency diseases. The company operates plasma collection centers, fractionates plasma, and commercializes plasma-derived therapeutics including Bivigam, Asceniv, and Nabi-HB. Principal revenue is derived from direct sales of specialized immune globulin products to specialty distributors, hospitals, and physician clinics. Core end markets encompass immunocompromised patients, clinical immunology practices, and hospital specialty departments across the United States. ADMA Biologics holds an established market position as an end-to-end plasma-derived biopharmaceutical manufacturer in North America. The company is headquartered in Ramsey, New Jersey, and its common stock trades on the Nasdaq Global Market.
5 of the funds FundTelligence covers report a position in ADMA Biologics.
- Legal name
- ADMA Biologics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 5
Funds holding ADMA Biologics
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.3 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.18 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.03 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)